deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT03141177

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Sponsor: Bristol-Myers Squibb

Conditions Renal Cell Carcinoma
Interventions Cabozantinib Ipilimumab Nivolumab Sunitinib
Updated 41 times since 2017 Last updated: May 23, 2025 Started: Jul 23, 2017 Primary completion: Feb 12, 2020 Completion: Jan 16, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Renal Cell Carcinoma and is currently ongoing. Bristol-Myers Squibb leads this study, which shows 41 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~May 2020 · 9 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Nov 2021 · 8 months · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

41 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  3. May 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 36 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Nov 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  9. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  10. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  12. Mar 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  14. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  15. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  16. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  17. Aug 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  18. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  19. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  20. Feb 2019 — May 2019 [monthly]

    Recruiting PHASE3

  21. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  22. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  23. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  24. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  25. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  26. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  27. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  28. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  29. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  30. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  31. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  32. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  33. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  34. Aug 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  35. Jul 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE3

  36. Jun 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Exelixis
  • Ono Pharmaceutical Co. Ltd
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Adachi-ku, Japan , Akita, Japan , Allentown, United States , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Arezzo, Italy , Athens, Greece , Athens, United States , Aurora, United States and 108 more locations